Fundación Santiago Dexeus Font
Clinical trials sponsored by Fundación Santiago Dexeus Font, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a lighter touch in IVF yield healthier embryos for women over 35? Results expected Dec 2026 (estimated)
- IVF breakthrough? lower progesterone dose tested in 1,020 women Results expected Jun 2027 (estimated)
- New IVF combo may boost fertility in older women Results expected Aug 2027 (estimated)
-
Could a lighter touch in IVF yield healthier embryos for women over 35?
Disease control Recruiting nowThis trial tests whether a lower daily dose of the fertility drug Rekovelle can produce as many healthy embryos as a higher dose in women of advanced age undergoing IVF with genetic screening. Participants receive either 15 or 20 micrograms per day during ovarian stimulation. Res…
Phase 4 • Sponsor: Fundación Santiago Dexeus Font • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New IVF combo may boost fertility in older women
Disease control Recruiting nowThis study tests whether adding a hormone called LH to standard IVF treatment helps women over 35 who had a low number of eggs in previous cycles. Participants will receive either the usual FSH hormone alone or FSH plus LH, and researchers will measure hormone levels on the day o…
Phase 4 • Sponsor: Fundación Santiago Dexeus Font • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
IVF breakthrough? lower progesterone dose tested in 1,020 women
Disease control Recruiting nowThis phase 3 trial tests whether a lower daily dose (600 mg) of vaginal progesterone works as well as the standard dose (800 mg) for supporting pregnancy after a frozen embryo transfer. About 1,020 women undergoing IVF will be randomly assigned to one of the two doses. The main g…
Phase 3 • Sponsor: Fundación Santiago Dexeus Font • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC